Abstract
Osteosarcoma is the most common malignant primary bone tumor in childhood. Despite multiagent chemotherapy and aggressive surgical resection, 30% of patients with localized disease and 80% of patients with metastatic disease at diagnosis will relapse. Survival for these patients has remained unchanged over the past 20 years. A number of novel agents in various stages of development hold promise for improving therapy for patients with osteosarcoma. This article will focus on novel therapeutic approaches, including agents targeting signal-transduction pathways, inhibitors of the tumor microenvironment and immunomodulatory agents, as well as overcoming resistance mechanisms and the use of novel delivery mechanisms.
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage
-
Animals
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bone Neoplasms / drug therapy*
-
Bone Neoplasms / surgery
-
Chemotherapy, Adjuvant
-
Child
-
Clinical Trials as Topic
-
Combined Modality Therapy
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Diphosphonates / administration & dosage
-
Docetaxel
-
Dogs
-
Drug Delivery Systems
-
Folic Acid Antagonists / administration & dosage
-
Gemcitabine
-
Humans
-
Immunologic Factors / administration & dosage
-
Neoadjuvant Therapy
-
Neoplasm Proteins / antagonists & inhibitors
-
Osteosarcoma / drug therapy*
-
Osteosarcoma / surgery
-
Protein Kinase Inhibitors / administration & dosage
-
Radiopharmaceuticals / therapeutic use
-
Signal Transduction / drug effects
-
Survival Rate
-
Taxoids / administration & dosage
-
Xenograft Model Antitumor Assays
-
Young Adult
Substances
-
Angiogenesis Inhibitors
-
Diphosphonates
-
Folic Acid Antagonists
-
Immunologic Factors
-
Neoplasm Proteins
-
Protein Kinase Inhibitors
-
Radiopharmaceuticals
-
Taxoids
-
Deoxycytidine
-
Docetaxel
-
Gemcitabine